Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Intervacc has carried out a directed issue of approximately 6.5 million shares, raising gross proceeds of approximately SEK 147 million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Stockholm 16 June 2020 Intervacc AB (publ) (”Intervacc” or the ”Company”) (Nasdaq First North Growth Market: IVACC) hereby announces that the Company has successfully completed a directed issue of 6,537,973 shares, at a subscription

Smoke development in a container at Azelio's development center in Åmål

On Tuesday evening, June 16, smoke development was reported in a container at Azelio's development center in Åmål. Azelio's staff was first on-site followed by the fire department. A minor smoldering fire from leaked sodium outside the system generated smoke and a passive extinguishing work was performed, after which the smoldering fire went out and smoke generation ceased. No person was injured in the incident. The container contained, among other things, two of Azelio's energy storage units. At a first assessment, the incident is not attributable to Azelio's technology and the damage

poLight ASA – results of the Subsequent Offering

Reference is made to previous announcements by poLight ASA (the "Company") regarding a subsequent offering of 181,818 new shares in the Company (the "Subsequent Offering" and the "Offer Shares"), each with a par value of NOK 0.20, and each Offer Share at a subscription price of NOK 55. Reference is furthermore made to the resolution by the general meeting of the Company on 28 May 2020 regarding the share capital increase pertaining to the Subsequent Offering. The subscription period for the Subsequent Offering expired at 16:30 CEST on 16 June 2020.  At the expiry of the subscription

Vestas wins first Enventus order in USA for 336 MW project from Taaleri Energia, AIP and Akuo Energy

News release from Vestas-American Wind TechnologyPortland, 16 June 2020Vestas has received a 336 MW order from the Taaleri SolarWind II fund and co-investors, AIP and Akuo Energy for the Escalade wind project in Texas, USA which will feature the first Enventus platform turbines in the USA. The project is the first North American wind project for Taaleri Energia and the Taaleri SolarWind II fund. The order includes supply, installation, and commissioning of 45 V162-5.6 MW and 20 V150-4.2 MW turbines as well as a 30-year Active Output Management 5000 (AOM 5000) service agreement,

Resolutions at Pharmacolog AB’s (publ) extraordinary general meeting June 16 2020

The shareholders of Pharmacolog in Uppsala AB (publ) held the Extraordinary General Meeting on June 16, 2020 in Uppsala. (information below in Swedish only)EmissionsbemyndigandenStämman beslutade att bemyndiga styrelsen att, vid ett eller flera tillfällen, för tiden intill nästa årsstämma, fatta beslut om emission av aktier, teckningsoptioner och/eller konvertibler. Styrelsen skall kunna besluta om emission med avvikelse från aktieägarnas företrädesrätt och/eller med bestämmelse om apport, kvittning eller eljest med villkor. Styrelsen skall kunna fatta beslut som innebär att

Resolutions at Eniro’s annual general meeting 2020

Eniro AB (publ) (“Eniro” or “the Company”) today held its Annual General Meeting (AGM), which made all resolutions in accordance with the nomination committee’s and the board of directors’ proposals, including a resolution on continued operations of the Company. The AGM voted in favour of the following resolutions, among others: 1. Adoption of the income statement and balance sheet, and of the consolidated income statement and the consolidated balance sheet for 2019. 2. Appropriation of the Company’s result in accordance with the board of directors’ proposal, entailing that no

A future alternative to hormonal treatment for prostate cancer

At this year's cancer congress in Chicago (ASCO), novel hormone treatments of patients suffering from non-metastatic castration-resistant prostate cancer were recognized. There are currently no efficient treatment options for the condition. Prostate cancer is the most common form of cancer in the western world. Every year, approximately 600,000 new cases are diagnosed in the US and Europe, and about 60,000 of these men develop prostate cancer recurrence[1]. Since 2003, SpectraCure  is working on a therapy with a strong potential to eliminate the cancer tumour

SBB presents new targets

Ahead of Samhällsbyggnadsbolaget I Norden AB (publ)’s (”SBB”) Capital Markets Day, the company presents updated financial targets. The company’s new growth target is that the profit from property management per A and B ordinary share shall on average grow with more than 15 per cent per year over a five-year period. Furthermore, the property portfolio value shall amount to SEK 125bn by 2025. The company’s Board of Directors also has the intention to enable the redemption of the remaining outstanding preference shares during the autumn, with the purpose to clarify the share structure; meaning

Kojamo Plc: Managers` Transactions

Kojamo Plc Stock Exchange Release, 16 June 2020 at 6:55 p.m. EESTManagers' Transactions Kojamo Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Jani Nieminen Position: Chief Executive Officer Issuer: Kojamo Oyj LEI: 7437007YPUOQZ8OV1R42 Notification type: INITIAL NOTIFICATION Reference number: 7437007YPUOQZ8OV1R42_20200616134908_6 ____________________________________________ Transaction date: 2020-06-15 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: SHARE ISIN:

Stillfront explores the conditions for conducting a directed share issue

NOT FOR DISTRIBUTION IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, HONG KONG, JAPAN, CANADA, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES.   Press releaseStockholm 2020-06-16Stillfront Group AB (publ) (“Stillfront” or "Company”) intends to raise proceeds through a directed share issue to provide the Company further financial strength and flexibility to be able to act swiftly on potential future acquisitions and growth opportunities.

Intervacc intends to carry out a directed share issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE , IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.  Stockholm 16 June 2020 Intervacc AB (publ) (”Intervacc” or the ”Company”) (Nasdaq First North Growth Market: IVACC) hereby announces its intention to carry out a directed share issue of a maximum of 15 percent of the total number of

Artificial Solutions intends to undertake a directed new share issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES PURSUANT TO APPLICABLE LAW. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.Artificial Solutions International AB (“Artificial Solutions” or the “Company”) today announces its intention to carry out a directed new share issue of up to SEK

EAB GROUP PLC: ACQUISITION OF OWN SHARES 16.06.2020

EAB GROUP PLC NOTIFICATION 16.06.2020 at 18:30 EAB GROUP PLC: ACQUISITION OF OWN SHARES 16.06.2020 Date 16.06.2020Exchange transaction BuyShare class EABAmount 895Average price/share 2.2400 EURHighest price/share 2.2400 EURLowest price/share 2.2400 EURTotal price 2,004.80 EUR The shares held by EAB Group Plc on 16.06.2020: EAB 23,696 On behalf of EAB Group Plc  Skandinaviska Enskilda Banken AB (Publ) Antti Salakka         Mikko Virtanen For more information, please

Comment from Telia Company related to media reports regarding Turkcell Holding divestment

Telia Company notes speculations in the media regarding a potential divestment of its stake in Turkcell Holding and can confirm that discussions are currently ongoing with Turkey Wealth Fund regarding a potential divestment of its indirect stake in Turkcell for approximately 530 MUSD.Negotiations are still ongoing and are in an advanced stage, but no agreement has yet been reached. Telia Company has no further comments at this stage but will communicate further if and when appropriate. Telia Company owns 47.1 percent of Turkcell Holding, a holding company owned by Cukurova, LetterOne and

Diaverum continues to grow its international presence by acquiring the CTN clinic in São Paulo, Brazil

Diaverum, a leading global renal care service provider, continues to increase its renal care services in Brazil through the acquisition of CTN – Clínica de Nefrologia Ltda, a clinic based in Mauá, greater São Paulo.The acquisition is another milestone for Diaverum in Brazil, which since entering the market in 2018, has expanded to provide life enhancing renal care at nine clinics, treating more than 3,200 patients across the country. “This acquisition reinforces our presence in Brazil and our commitment to the renal patients and the healthcare system of the country. CTN is a strategic,

#20-209 Delisting of certain Derivatives from NGM

Certain derivatives will be delisted from NGM.For more details see attached files. For further information concerning this NGM notice please contact: Listing department on +46 8 566 390 20 or at listings@ngm.se Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

#20-208 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details see attached file. For further information concerning this NGM notice please contact: Listing on +46 8 566 390 20 or at listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

Bong obtained approval from noteholders to the request of amendments of terms and conditions of its outstanding senior notes

Bong AB (publ) (the “Company”) initiated a written procedure (the “Written Procedure”) on 22 May 2020 in relation to its outstanding SEK 210 million senior secured floating rate notes 2018/2021 with ISIN SE0011281419 (the “Notes”) to seek the noteholders’ approval of the proposal for certain amendments to the terms and conditions of the Notes. The deadline for voting under the Written Procedure was at 15:00 (CEST) today, 16 June 2020. A sufficient number of noteholders participated in the Written Procedure to form a quorum, and a sufficient number of the Adjusted Nominal Amount for which

Veidekke ASA: Clarification regarding sales price

Regarding today’s annoucement that Veidekke divests its property development operation, the company wishes to clarify that the amount of NOK 7.7 billion is the cash payment to the company on a debt-free basis. The buyer takes over the operation based on an enterprise value of NOK 8.75 billion including working capital, taxes and other debt items.As stated in the previous stock exchange release, the transaction will generate a posted gain for Veidekke of approximately NOK 1.2 billion. For more information, contact: Jimmy Bengtsson, Group CEO, ph. +47 984 70 000, jimmy.bengtsson@

Decisions by NoHo Partners Plc Annual General Meeting

NoHo Partners PlcSTOCK EXCHANGE RELEASE 16 June 2020 at 17:10DECISIONS BY NOHO PARTNERS PLC ANNUAL GENERAL MEETING NoHo Partners Plc’s Annual General Meeting was held in Tampere today, 16 June 2020. The meeting adopted the financial statements for 2019 and discharged the company’s management from liability. The Annual General Meeting decided that, based on the balance sheet adopted for the financial period that ended on 31 December 2019, no dividends will be distributed. The Annual General Meeting decided that the Board of Directors comprise six (6) members and selected Ernst & Young

Observe Medical ASA – Rights issue approved by the extraordinary general meeting

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.   Reference is made to Observe Medical ASA's (the "Company") stock exchange announcements published on 26 May 2020, 15 June 2020 and 16 June 2020 respectively, regarding a proposed fully underwritten

Stayble’s clinical phase 2b study has started

Stayble announces today, June 16, 2020, that the Company´s clinical phase 2b study with STA363 has started with the first clinic in Russia being initiated and now recruiting patients. STA363 is targeting patients suffering from chronic low back pain caused by disc degeneration.The primary goal of the phase 2b trial is to demonstrate safety, tolerability and a clinically relevant reduction in pain in patients. The study will include some 100 patients and will be conducted at about 20 clinical sites in the Netherlands, Russia and Spain. CEO Andreas Gerward comments: The initiation of the

Observe Medical ASA – Correction: Terms of the underwritten rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS STOCK EXCHANGE ANNOUNCEMENT.   Reference is made to Observe Medical ASA's (the "Company") stock exchange announcement published yesterday, on 15 June 2020, regarding the terms of the proposed fully underwritten rights issue in the

There are no items matching the current filter
There are no more items matching the current filter
Back to top